Brief: China Medical System Says 'Tildrakizumab' Granted Approval For Drug Clinical Trial
Aug 19 (Reuters) - China Medical System Holdings Ltd
0867.HK :
* 'TILDRAKIZUMAB' GRANTED APPROVAL FOR DRUG CLINICAL TRIAL
ISSUED
FROM NMPA
Source text for Eikon: ID:nHKS4ydH9n
Further company coverage: 0867.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on China Medical System Holdings
See all newsBrief: China Medical System Says CMS-D001 Granted Drug Clinical Trial Approval Notice By NMPA
Brief: China Medical System Holdings Says Dermavon Receives NMPA Approval For Lumirix NDA For Atopic Dermatitis
China Medical System climbs most in six weeks on higher profit, dividend
China Medical System H1 revenue rises on jump in sales of innovative and exclusive products
AI shortens drug discovery to around 1 year in China, Insilico CEO says